Integrative neuroscience approach to predict ADHD stimulant response

@article{Hermens2006IntegrativeNA,
  title={Integrative neuroscience approach to predict ADHD stimulant response},
  author={Daniel F. Hermens and D. L. Rowe and Evian Gordon and Leanne M. Williams},
  journal={Expert Review of Neurotherapeutics},
  year={2006},
  volume={6},
  pages={753 - 763}
}
Despite high rates of prescription, little is known about the long-term consequences of stimulant medication therapy for attention-deficit hyperactivity disorder (ADHD) sufferers. Historically, the clinical use of stimulants for ADHD has been based on trial and error before optimal therapy is reached. Concurrently, scientific research on the mechanism of action of stimulants has influenced neurobiological models of ADHD, but has not always informed their prescription. Whilst the two main… Expand
Drug Therapy of Attention Deficit Hyperactivity Disorder: Current Trends
TLDR
Current trends in drug therapy of ADHD are discussed, the promise pharmacogenomics may hold in the future is highlighted, and the use of nonstimulant drugs like atomoxetine and various other drugs, such as a-agonists, and a few antidepressants, being used in an off-label manner are highlighted. Expand
tomoxetine Improved Response Inhibition in Adults ith Attention Deficit/Hyperactivity Disorder
ttention-deficit/hyperactivity disorder (ADHD) affects 3%–7% of children and is characterized by problems with impulsivity, inattention, and hyperactivity (1). At least 50% of hese children stillExpand
Atomoxetine Improved Response Inhibition in Adults with Attention Deficit/Hyperactivity Disorder
TLDR
At atomoxetine treatment in the ADHD patients was associated with shorter stop-signal reaction times and lower numbers of commission errors on the sustained attention task, and improved inhibitory control, most likely via noradrenergically mediated augmentation of prefrontal cortex function. Expand
Neuroimaging markers for the prediction of treatment response to Methylphenidate in ADHD.
TLDR
Some promising findings have been identified and they should motivate additional work to establish more reliable neuroimaging markers of treatment response to MPH in ADHD. Expand
Single-dose effects on the P3no-go ERP component predict clinical response to stimulants in pediatric ADHD
TLDR
Clinical response to stimulants can be predicted by assessing single-dose changes in the P3no-go ERP component amplitude, which may be a clinically useful marker of response to Stimulant medication. Expand
Neuroimaging-Aided Prediction of the Effect of Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder: A Randomized Controlled Trial
Although methylphenidate hydrochloride (MPH) is a first-line treatment for children with attention-deficit hyperactivity disorder (ADHD), the non-response rate is 30%. Our aim was to develop aExpand
Effects of methylphenidate on the ERP amplitude in youth with ADHD: A double-blind placebo-controlled cross-over EEG study
TLDR
It is suggested that mental fatigue plays a role in the decrease of the P3 response in the placebo condition compared to pre-placebo, a phenomenon that is significant in ADHD subjects but not in controls, and which is interestingly rectified by MPH. Expand
Off-label prescription of quetiapine in psychiatric disorders
  • D. Rowe
  • Medicine
  • Expert review of neurotherapeutics
  • 2007
TLDR
It is suggested that low-dose quetiapine shows good tolerability and efficacy in patients diagnosed with these disorders, particularly in the case of treatment-resistant patients that do not respond to primary treatments including SSRIs and cognitive–behavioral therapy. Expand
Treatment-resistant attention-deficit hyperactivity disorder: Clinical significance, concept, and management
TLDR
It is suggested that the more ideal strategy of defining treatment resistance should consider the improvement of ADHD symptoms and the global functioning simultaneously, and the optimal medication adjustment or the combination of medications and psychotherapy may be the potential therapeutic strategy for treatment-resistant ADHD. Expand
Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database
TLDR
Reductions in CAARS-Inv:SV and CGI-S scores at weeks 4 and 10 are statistically significant predictors of response to atomoxetine at later time points in adults with ADHD, but the predictors identified by these analyses are not reliable enough for use in clinical practice. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 116 REFERENCES
Non-Stimulant Treatment of Attention-Deficit/Hyperactivity Disorder
TLDR
Clinical guidelines for each of these agents, as well as their use in combination with stimulants in comorbid conditions, will be discussed. Expand
Predicting stimulant medication response in ADHD: evidence from an integrated profile of neuropsychological, psychophysiological and clinical factors.
TLDR
The value of integrating neuropsychological and psychophysiological data in predicting medication response in ADHD is indicated, as better response was associated with increased resting beta power and decreased WM distractor P3. Expand
Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration
  • M. Solanto
  • Medicine, Psychology
  • Behavioural Brain Research
  • 1998
The psychostimulants, D-amphetamine (D-AMP) and methylphenidate (MPH), are widely used to treat attention-deficit hyperactivity disorder (ADHD) in both children and adults. The purpose of this paperExpand
The challenge of predicting which children with Attention Deficit-Hyperactivity Disorder will respond positively to methylphenidate
Predicting which children with Attention Deficit-Hyperactivity Disorder (ADHD) will respond to methylphenidate (MPH; Ritalin) is of theoretical interest, for example, for understanding catecholamineExpand
Stimulant Effects in Attention Deficit Hyperactivity Disorder: Theoretical and Empirical Issues
  • C. Denney
  • Psychology, Medicine
  • Journal of clinical child psychology
  • 2001
TLDR
This discussion suggests that theory-based experimental manipulations of task and setting variables designed to impose challenge on hypothesized core features of the disorder are more likely to yield insights into the causal mechanisms governing behavioral organization in affected children than strategies emphasizing static identification of diagnostic correlates. Expand
Effect of Methylphenidate on Attention in Children with Attention Deficit Hyperactivity Disorder (ADHD): ERP Evidence
TLDR
Differential dosage effects and a dissociation between dose levels and aspects of processing are suggested in ADHD, with the ADHD group at baseline was more impulsive and inattentive than controls. Expand
Stimulant treatment for children: a community perspective.
TLDR
In this area of the Great Smoky Mountains, stimulant treatment was being used in ways substantially inconsistent with current diagnostic guidelines. Expand
Attention-deficit/hyperactivity disorder (adhd) as a noradrenergic disorder
TLDR
Brain imaging studies fit well with the idea that dysfunction in fronto-subcortical pathways occurs in ADHD with its underlying dysregulation of noradrenergic function, and neurobiological and pharmacological data provide compelling support for a nor adrenergic hypothesis of ADHD and suggest that drugs with noradRenergic activity may play an important role in the therapeutics of this disorder. Expand
Methyiphenidate vs. amphetamine: Comparative review
This article compares the two most common medications for Attention-Deficit/Hyperactivity Disorder (ADHD), using data from controlled studies. Medline and Psychinfo searches were done for 1984-1996Expand
Attention-deficit/hyperactivity disorder: a life-span perspective.
  • J. Biederman
  • Medicine, Psychology
  • The Journal of clinical psychiatry
  • 1998
TLDR
A variety of pharmacologic agents are available in treating ADHD: stimulant medications remain the first-line treatment for noncomorbid ADHD, whereas tricyclic antidepressants and bupropion are recommended for stimulant nonresponders and patients with more than one psychiatric disorder. Expand
...
1
2
3
4
5
...